Israeli biotech Kamada announced positive results in pre-clinical trials of its Alpha-1 Antitrypsin (AAT) protein. AAT has potential for treating bacterial lung infections and also to prevent implant rejection. AAT is the active ingredient in Kamada’s Glassia , used to treat emphysema.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000795692&fid=1725